Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861), a ...

REGISTER Employers provide health coverage for over 150 million Americans, giving them a unique opportunity to drive ...

Takeda announces positive results from two pivotal phase 3 studies of oveporexton in narcolepsy type 1: Osaka Wednesday, July 16, 2025, 16:30 Hrs [IST] Takeda, a global company fo ...

AI solutions are also involved in the studies, said the company. "New technologies, including AI, as well as other technologies, are completely transforming our industry as the way we do research and ...

Investing.com -- Takeda Pharmaceutical Co Ltd ADR (NYSE: TAK) stock rose 3.5% following the announcement of positive Phase 3 trial results for its investigational narcolepsy treatment oveporexton. The ...

Japan’s largest pharma company Taked today announced that all primary and secondary endpoints were met in two Phase III ...

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK) shares rose 3.5% following the announcement of encouraging Phase 3 trial results ...

Of the patients across the two Phase III studies, more than 95% enrolled in the ongoing long-term extension (LTE) study.

Investing.com -- Takeda Pharmaceutical Co Ltd ADR (NYSE: TAK) stock rose 3.5% following the announcement of positive Phase 3 trial results for its investigational narcolepsy treatment oveporexton ...

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

Oveporexton is a testament to Takeda’s strength in discovering and developing a potential new class of medicines for difficult to treat diseases such as narcolepsy type 1,” said Christophe Weber, ...